Breaking News

Financial Report: Emergent BioSolutions

By Kristin Brooks | March 7, 2014

2013 revenues up 11%

Emergent BioSolutions

4Q Revenues: $98.1 million (+4%)

4Q Earnings: $15.2 million (-6%)

FY Revenues: $312.7 million (+11%)

FY Earnings: $31.1 million (+32%)

Comments: For the year, product sales were $257.9 million, up 19%, driven by the biodefense business with strong performance reflected by the increased BioThrax doses shipped and sales of newly acquired medical countermeasure RSDL.
Contracts and grants revenues were $54.8 million, down 17% primarily due to decreased revenue associated with BioThrax PEP and PreviThrax development activities, offset by revenue associated with CIADM contract with BARDA. R&D expenses were flat at $119.9 million for the year. In the quarter, the company announced the acquisition of Cangene Corp., which added three Biodefense countermeasures, four commercial products, an infrastructure focused on hospitals and specialty clinics, and a growing contract manufacturing and fill/finish business.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016